Levels of methylated arginines and L-arginine in patients with polycystic ovary syndrome: a promising approach in clinical evaluation

Abstract

Aim: Polycystic ovary syndrome (PCOS) is a prevalent disease in women. PCOS is related with metabolic syndrome and associated with cardiovascular disorders. Methylated arginine is involved in endothelial dysfunction, inflammation and atherosclerosis pathophysiology. Our aim is to determine the association between PCOS and methylated arginine metabolites in order to investigate the role of vascular factors in the etiopathogenesis of PCOS. Material and Method: This is a case-control study. The study group is consisted of 45 PCOS cases and 45 controls. The case group is patients who applied to Department of Gynecology and diagnosed with PCOS. Control group is consisted of healthy volunteers who applied to the outpatient clinics for other reasons. The study took place in Department of Gynecology in XX hospital. Data collection was held between 2018 October to 2019 June. Methylated arginine derivatives such as ADMA, SDMA, L-NMMA (L-NG-monomethyl Arginine Acetate) and also arginine and citrulline were determined. Results: ADMA, SDMA, L-NMMA, arginine, citrulline, Arginine/ADMA, SDMA/ADMA and total methylarginine parameters showed statistically significant differences between groups. Strong positive relation was determined between scoring of Ferriman-Gallway (FGS) and luteinizing hormone (LH), glucose, insulin, ADMA, citrulline, homoarginine, L-NMMA and total methylarginine levels. Conclusions: High levels of methylated arginine/NO pathway metabolites in PCOS patients may be related with cardiovascular outcomes of PCOS.